Caribou Biosciences to Participate in the Oppenheimer 33rd Annual Healthcare Conference
Caribou Biosciences (Nasdaq: CRBU), a leader in CRISPR genome-editing, announced that its CEO, Rachel Haurwitz, will participate in a fireside chat at the Oppenheimer 33rd Annual Healthcare Conference on March 15, 2023, at 10:40 am EDT. This event will showcase Caribou's advancements in gene-editing technologies, particularly their innovative CRISPR hybrid RNA-DNA guides (chRDNAs), aimed at enhancing precision in genome editing. The live webcast can be accessed on Caribou's website, available for 30 days post-event. The company focuses on developing transformative therapies for serious diseases using its proprietary technology.
- None.
- None.
BERKELEY, Calif., March 08, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz, PhD, Caribou’s president and chief executive officer, is scheduled to participate in a fireside chat at the virtual Oppenheimer 33rd Annual Healthcare Conference on March 15, 2023, at 10:40 am EDT.
Register for the live webcast by visiting the Events page on Caribou’s website. The webcast will be available on the Caribou website for 30 days after the event.
About Caribou’s Novel Next-Generation CRISPR Platform
CRISPR genome editing uses easily designed, modular biological tools to make DNA changes in living cells. There are two basic components of Class 2 CRISPR systems: the nuclease protein that cuts DNA and the RNA molecule(s) that guide the nuclease to generate a site-specific, double-stranded break, leading to an edit at the targeted genomic site. CRISPR systems are capable of editing unintended genomic sites, known as off-target editing, which may lead to harmful effects on cellular function and phenotype. In response to this challenge, Caribou has developed CRISPR hybrid RNA-DNA guides (chRDNAs; pronounced “chardonnays”) that direct substantially more precise genome editing compared to all-RNA guides. Caribou is deploying the power of its Cas12a chRDNA technology to carry out high efficiency multiple edits, including multiplex gene insertions, to develop CRISPR-edited therapies.
About Caribou Biosciences, Inc.
Caribou Biosciences is a clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company’s genome-editing platform, including its proprietary Cas12a chRDNA technology, enables superior precision to develop cell therapies that are armored to potentially improve antitumor activity. Caribou is advancing a pipeline of off-the-shelf cell therapies from its CAR-T and CAR-NK platforms as readily available treatments for patients with hematologic malignancies and solid tumors.
For more information about Caribou, visit www.cariboubio.com and follow the company @CaribouBio.
“Caribou Biosciences” and the Caribou logo are registered trademarks of Caribou Biosciences, Inc.
Caribou Biosciences Contacts:
Investors:
Amy Figueroa, CFA
afigueroa@cariboubio.com
Media:
Peggy Vorwald, PhD
pvorwald@cariboubio.com
FAQ
What is Caribou Biosciences participating in on March 15, 2023?
Who is representing Caribou Biosciences at the conference?
What is the significance of Caribou's CRISPR hybrid RNA-DNA guides?
How can I watch the Caribou Biosciences webcast?
What innovations is Caribou Biosciences showcasing?
